H-FABP as a Biomarker for Transient Ischemic Attack

BHH member ABCDx, a leader in brain injury diagnostics, is proud to announce the acceptance of the article, "H-FABP as a Biomarker in Transient Ischemic Attack," for publication in the prestigious journal, Cardiovascular Translational Research. This pivotal study highlights the innovative use of Heart-type Fatty Acid Binding Protein (H-FABP) as a diagnostic biomarker for Transient Ischemic Attack (TIA).

The study, conducted by an esteemed team of researchers including Daisy Guamán-Pilco, Elvira Chocano, Elena Palà, Marcel Lamana-Vallverde, Anna Penalba, Paula García Rodríguez, Marta Rubiera, Alejandro Bustamante, Alex Rovira, Soledad Pérez-Sánchez, Leire Azurmendi-Gil, Sandrine Reymond, Jean-Charles Sanchez, and Joan Montaner, explores the potential of H-FABP in differentiating TIA from its mimics. The findings, derived from data involving 175 patients, demonstrated that H-FABP levels were significantly higher in individuals with TIA compared to those with mimic conditions, showcasing the biomarker's discriminative power.

ABCDx has harnessed this groundbreaking research to develop VasCheck, a rapid test utilizing H-FABP, designed for point-of-care testing. The VasCheck system, complemented by the VasCheck reader, allows for quick and reliable measurement of H-FABP levels, facilitating early and accurate diagnosis of TIA in emergency and primary care settings.

Joan Montaner, co-author of the study and Chief Medical Officer at ABCDx, stated, "The acceptance of our study underscores the importance of H-FABP as a promising biomarker for TIA. The rapid application of point-of-care tests (POCT) for H-FABP measurement, as demonstrated by our VasCheck test, supports its potential use in real-world clinical settings, providing a significant advantage in the early diagnosis and treatment of TIA."

Discover more HERE.